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Summary
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Model organisms and human studies have led to increasing empirical evidence that interactions
among genes contribute broadly to genetic variation of complex traits. In the presence of gene-bygene interactions, the dimensionality of the feature space becomes extremely high relative to the
sample size. This imposes a significant methodological challenge in identifying gene-by-gene
interactions. In the present paper, through a Gaussian graphical model framework, we translate the
problem of identifying gene-by-gene interactions associated with a binary trait D into an inference
problem on the difference of two high-dimensional precision matrices, which summarize the
conditional dependence network structures of the genes. We propose a procedure for testing the
differential network globally that is particularly powerful against sparse alternatives. In addition, a
multiple testing procedure with false discovery rate control is developed to infer the specific
structure of the differential network. Theoretical justification is provided to ensure the validity of
the proposed tests and optimality results are derived under sparsity assumptions. A simulation
study demonstrates that the proposed tests maintain the desired error rates under the null and have
good power under the alternative. The methods are applied to a breast cancer gene expression
study.
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Supplementary material available at Biometrika online includes more extensive simulation esults comparing the numerical
performance of the proposed global test with that of other tests, the proofs of Lemmas 2, 3 and 4, and the Matlab code for numerical
implementation.
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1. INTRODUCTION
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High throughput technologies, enabling comprehensive monitoring of a biological system,
have fundamentally transformed biomedical research. Studies using such technologies have
led to successful molecular classifications of diseases into clinically relevant subtypes and
genetic signatures predictive of disease progression and treatment response (van’t Veer et al.,
2002; Gregg et al., 2008; Hu et al., 2009, e.g.). Irrespective of the technology used, analysis
of high-throughput data typically considers one marker at a time and yields a list of
differentially expressed genes or proteins. On the other hand, epistasis, or interactions
between genes, has long been recognized as crucial to understanding the genetic architecture
of disease phenotypes (Phillips, 2008; Eichler et al., 2010). Increasing empirical evidence
from model organisms and human studies suggests that gene-by-gene interactions may make
an important contribution to total genetic variation of complex traits (Zerba et al., 2000;
Marchini et al., 2005). In this paper, we are specifically interested in gene-by-gene
interactions with respect to the interactive effects of two genes on a binary disease trait D.

Author Manuscript

In the presence of gene-by-gene interactions, the dimensionality of the feature space
becomes extremely high relative to the sample size. This, together with the variability of the
data, imposes a significant methodological challenge in identifying gene-by-gene
interactions using currently available studies, which typically have limited sample sizes and
power. Recent development in interaction modeling has led to several useful methods
including multi-factor dimensionality reduction (Ritchie et al., 2001; Moore, 2004),
polymorphism interaction analysis (Mechanic et al., 2008), random forests (Breiman, 2001),
various variations of logistic regression with interactive effects (Chatterjee et al., 2006;
Chapman & Clayton, 2007; Kooperberg & Ruczinski, 2005; Kooperberg & LeBlanc, 2008)
and sure independence screening (Fan & Lv, 2008). However, to overcome the high
dimensionality, a majority of these methods use multistage procedures and marginal
assessments of the effects of a gene pair without simultaneously accounting for the effects of
other genes. Multistage procedures may have limited power in detecting genes that affect the
outcome through interactions with other genes without strong main effects. The interactive
effects detected through models that only consider one pair of genes at a time without
conditioning on other genes may also result in false identification of interactions due to the
discrepancy between conditional and unconditional effects. Furthermore, none of the
existing methods provide false discovery rate control in the presence of interactions. Due to
the large number of tests, the power of multiple testing procedures using the standard
Bonferroni or naive false discovery rate corrections can dissipate quickly.
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In this paper, through a Gaussian graphical model framework, we translate the problem of
identifying gene-by-gene interactions associated with a binary trait D into the comparison of
two high-dimensional precision matrices. Let G denote a p × 1 vector of genomic markers
and assume that, conditional on D = d, G ~ N(μd, Σd), for d = 1, 2. Then the posterior risk
given G is
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where g(x) = ex/(1 + ex) and
is the precision matrix for G conditional on
D = d. Hence, an interaction between the gene pair (i, j) affects the disease risk if and only if
δi,j= ωi,j,1 − ωi,j,2 = 0. The difference between the two precision matrices, denoted by Δ =
(δi,j) = Ω1 – Ω2, is called the differential network. This type of model for a differential
network has been used in Li et al. (2007) and Danaher et al. (2014). We thus propose to test
for gene-by-gene interactions both by testing the global hypotheses
(1)

and by simultaneously testing the hypotheses

Author Manuscript

while controlling for the overall false discovery rate at a pre-specified level.
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Few authors have considered testing the equality of two precision matrices in the highdimensional setting. The global null hypothesis Δ = 0, or equivalently Ω1 = Ω2, corresponds
to the hypothesis that none of the gene pairs have interactive effects on D. The equality of
two precision matrices is equivalent to the equality of two covariance matrices, and the latter
has been studied under various alternatives. Under the dense alternative, where Σ1 and Σ2
differ in a large number of entries, various sum-of-square type testing procedures have been
proposed (Schott, 2007; Srivastava & Yanagihara, 2010; Li & Chen, 2012). Under the sparse
alternative with Σ1 and Σ2 differing only in a small number of entries, Cai et al. (2013)
introduced a particularly powerful test. However, in the gene-by-gene interaction setting, the
goal is to identify the structure of the differential network. In such cases, it is often
reasonable to assume that Δ is sparse, while Σ1 – Σ2 is not. Hence, testing procedures that
can leverage information on the sparsity of Δ may improve power. Furthermore, due to the
fundamental difference between conditional and unconditional dependences, the various
procedures for testing the covariance matrices may not be well adapted to testing specific
entries of the precision matrices.
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The first goal of this paper is to develop a global test for H0 : Δ = 0 that is powerful against
sparse alternatives. We then develop a multiple testing procedure for simultaneously testing
the hypotheses {H0,i,j : 1 ≤ i < j ≤ p} with false discovery rate control to infer the structure of
the differential network. In the high-dimensional setting, there is no sample precision matrix
that one can use to approximate Ωd. We propose to infer Ωd by relating its elements to the
coefficients of a set of regression models for G conditional on D = d. We then construct test
statistics based on the covariances between the residuals from the fitted regression models.
The testing procedures are easy to implement. A Matlab implementation is available in the
Supplementary Material.

Biometrika. Author manuscript; available in PMC 2017 May 11.

Xia et al.

Page 4

Author Manuscript

2. Global Testing of Differential Networks
2.1. Notation and Definitions
In this section we consider testing the global hypothesis (1). We begin with notation and
definitions that will be used in the rest of the paper. Let Xk ε ℝp and Yk ε ℝp denote G
given D = 1 and D = 2, respectively, Xk ~ N(μ1,Σ1) for k = 1,…, n1, Yk ~ N(μ1,Σ2) for k = 1,
…, n2, where Σd = (σi,j,d) for d = 1, 2, and {Xk : k = 1,…, n1} and {Yk : k = 1,…, n2} are
independent observations from the two populations. Let X = (X1,…, Xn1)T and Y = (Y1,…,

Yn2)T denote the data matrices. Let

, for d = 1,2.

Author Manuscript

For subscripts, we use the convention that i stands for the ith entry of a vector and (i,j) for the
entry in the ith row and jth column of a matrix, k represents the kth sample and d indexes the
binary trait. Let βi,1 = (β1,i,1,…,βp−1,i,1)T denote the regression coefficients of Xk,i
regressed on the rest of the entries of Xk and let βi,2 = (β1,i,2,…,βp−1,i,2)T denote the
regression coefficients of Yk,i regressed on the rest of the entries of Yk.
For any vector μd with dimension p × 1, let μ−i,d denote the (p – 1) × 1 vector by removing
the ith entry from μd. For a symmetric matrix A, let λmax(A) and λmin(A) denote the largest
and smallest eigenvalues of A. For any p × q matrix A, Ai,−j denotes the ith row of A with its
jth entry removed and A−i,j denotes the jth column of A with its ith entry removed. The
matrix A−i,−j denotes a (p – 1) × (q – 1) matrix obtained by removing the ith row and jth
column of A. For an n × p data matrix U = (U1,…, Un)T, let

with

with dimension 1 × (p − 1), U(i) = (U1,i,…,

dimension
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Un,i)T with dimension

with dimension n × 1, where
with dimension n × (p − 1). For tuning

, and
parameters λ, let
on the sample size nd.

represent the

ith

tuning parameter for binary trait d, which depends

For a vector β = (β1,…,βp)T ε ℝp, define the ℓq norm by
for 1 ≤ q ≤ ∞.
A vector β is called k-sparse if it has at most k nonzero entries. For a matrix Ω = (ωi,j)p×p,
the matrix 1-norm is the maximum absolute column sum,
the matrix elementwise infinity norm is defined to be ||Ω||∞ = max1≤i,j≤p |ωi,j| and the

,

Author Manuscript

. For a matrix Ω, we say Ω is k-sparse if
elementwise ℓ1 norm is
each row/column has at most k nonzero entries. For a set ℋ, denote by |ℋ| the cardinality of
ℋ. For two sequences of real numbers {an} and {bn}, write an = O(bn) if there exists a
constant C such that |an| ≤ C|bn| holds for all n, write an = o(bn) if limn→∞ an/bn = 0, and
write an ≍ bn if there are positive constants c and C such that c ≤ an/bn ≤ C for all n.
2 2. Testing Procedure
It is well known (e.g., Anderson, 2003, Section 2.5), that in the Gaussian setting the
precision matrix can be described in terms of regression models. Specifically, we may write
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(2)

(3)

, are independent of Xk,−i

where
and Yk,−i respectively, and
vectors βi,d and the error terms εk,i,d satisfy

. The regression coefficient

Author Manuscript

where cov(·,·) denotes the population covariance. Since the null hypothesis H0 : Δ = 0 is
equivalent to the hypothesis

a natural approach to test H0 is to first construct estimators of ωi,j,d, and then base the test on
the maximum standardized differences. We first construct estimators of ri,j,d

Author Manuscript

Let

be estimators of βi,d satisfying
(4)

(5)

Estimators
that satisfy (4) and (5) can be obtained easily via methods such as the lasso
and Dantzig selector. See Section 2.3 for details. Define the residuals by

Author Manuscript

A natural estimator of ri,j,d is the sample covariance between the residuals,

(6)
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However, when
tends to be biased due to the correlation induced by the
estimated parameters and it is desirable to construct a bias-corrected estimator. Lemma 2
shows that

is the empirical covariance between {εk,i,d: k = 1,… ,nd} and {εk,j,d : k = 1,
where
…,nd}. For 1 ≤ i ≤ j ≤ p, βi,j,d = − ωi,j,d/ωj,j,d and βj−1,i,d = −ωi,j,d/ωi,i,d Thus, we propose a
bias-corrected estimator of ri,j,d as
(7)

Author Manuscript

The bias of

is of order max{ri,j,d(log p/nd)1/2,(ndlog p)−1/2}.

For i = j, note that ri,i,d = 1/ui,i,d. We show in Lemma 2 that

which implies that
is a nearly unbiased estimator of ri,i,d. A natural estimator of
ωi,j,d can then be defined by

Author Manuscript

(8)

We test H0 : Δ = 0 based on the estimators
The estimators Ti,j,1 − Ti,j,2 in are heteroscedastic and possibly have a wide range of
variability. We first standardize Ti,j,1 − Ti,j,2 before combining information from all entries in
. Let

and
. It will be shown in Lemma 2 that, uniformly in 1 ≤ i ≤ j

≤ p,

Author Manuscript

Let

where

. Note that

. We then estimate θi,j,d by
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Define the standardized statistics

(9)

Finally, we propose the following test statistic for testing the global null hypothesis H0,

Author Manuscript

(10)

The asymptotic properties of Mn will be studied in detail in Section 3. Intuitively, {Wi,j} are
approximately standard normal variables under the null H0 and they are only weakly
dependent under suitable conditions. Thus Mn is the maximum of the squares of p(p + 1)/2
such random variables, so its value should be close to 2 log{p(p + 1)/2} ≈ 4 log p under H0.
We show in Section 3 that, under certain regularity conditions, Mn − 4 log p − log log p
converges to a type I extreme value distribution under H0 : Δ = 0.
Based on the limiting null distribution of Mn, which will be developed in Section 3.1, we
define the test ψα by

Author Manuscript

(11)
where qα is the 1 − α quantile of the type I extreme value distribution with the cumulative
distribution function exp{(8π)−1/2e−t/2}, i.e.,
(12)

The hypothesis H0 is rejected whenever ψα = 1.
2.3. Data-driven estimation of regression coefficients

Author Manuscript

The testing procedure requires the estimation of regression coefficients βi,d, for i = 1,…,p
and d = 1, 2. Various estimators have been studied in the literature, including the lasso and
Dantizg selector. Here, we use the lasso by solving the optimization problem,

(13)
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(14)

where
and
, d = 1,2. Then by Proposition
4.2 of Liu (2013), under Condition (C1) given in Section 3 and a mild condition on the
sparsity of βi,d (i = 1,…, p, d = 1,2), the convergence rates in (4) and (5) can be guaranteed
by using any κd > 2. The result is formally stated in Corollary 1. In practice, κd = 2 works
well for global testing of H0 : Δ = 0, and for the multiple testing procedure with false
discovery rate control, a data-driven algorithm is proposed in Section 5 to select κd
adaptively.

Author Manuscript

2.4. Discussion
The global test ψα given in (11) is based on estimators of ωi,j,1 − ωi,j,2 Here we estimate
ωi,j,d by first constructing estimators for ri,j,d = ωi,j,d/(ωi,i,dωj,j,d), and then estimating ri,j,d
through bias correction of the residuals

defined in (7).

Liu (2013) considered multiple testing of entries of a single precision matrix Ω = (ωi,j). In
the one-sample case, ωi,j = 0 is equivalent to ri,j= ωi,j/(ωi,iωj,j) = 0 under the null and ri,j is
easier to estimate. The procedure in Liu (2013) is based on the estimation of ri,j instead of
ωi,j. However, in Section 4 we will also consider multiple testing between two groups, and
ωi,j,1= ωi,j,2 is not equivalent to ri,j,1= ri,j,2. Thus, it is necessary to construct testing
procedures based directly on estimators of ωi,j,1 − ωi,j,2.

Author Manuscript

Testing the global hypothesis H0 : Ω1 = Ω2 is equivalent to testing H0 : Σ1 = Σ2, which has
been well studied (Schott, 2007; Srivastava & Yanagihara, 2010; Li & Chen, 2012; Cai et al.,
2013). In particular, Cai et al. (2013) constructed a global test for H0 : Σ1 = Σ2 that is
powerful against the alternative where Σ1 − Σ2 is sparse. However, in many applications, the
goal is to learn the structure of the differential network, and we are interested in both testing
the global hypothesis H0 : Ω1 = Ω2 and multiple testing of the entrywise hypotheses H0,i,j :
ωi,j,1 = ωi,j,2. In such cases, it is often reasonable to assume that Δ = Ω1 − Ω2 is sparse, but
Σ1 − Σ2 is not. Hence, testing procedures for H0 : Σ1 = Σ2 cannot leverage information on the
sparsity of Δ and more importantly do not naturally lead to a multiple testing procedure for
simultaneously testing the entrywise hypotheses H0,i,j : ωi,j,1 = ωi,j,2.

3. Theoretical Results for the Global Test
Author Manuscript

3 1. Asymptotic Null Distribution of Mn
In this section, we analyze the properties of the new test for testing the global null
hypothesis H0 : Δ = 0, including the null distribution of the test statistic Mn, the asymptotic
size and power. We are particularly interested in the power of the new test under the
alternative with Δ sparse. We further show that the power is minimax rate optimal.
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Under assumptions (C1) and (C2), Theorem 1 indicates that under H0, Mn − 4 log p + log
log p converges weakly to a Gumbel random variable with distribution function
exp{−(8π)−1/2e−t/2}.
(C1)

Assume that log p = o(n1/5), n1 ≍ n2, and for some constant
such that | Aτ| =
d = 1 or 2}.

(C2)

o(p1/16)

, for d = 1,2. There exists some τ > 0
where Aτ = {(i,j) : |ωi,j,d| ≥ (log p)−2−τ, 1 ≤ i<j ≤ p, for

Let Dd be the diagonal of Ωd and let
, for d = 1,2.
Assume that max1≤i≤j≤p |ηi,j,d| ≤ ηd ≤ 1 for some constant 0 < ηd < 1.

Author Manuscript

Condition (C1) on the eigenvalues is a common assumption in the high-dimensional setting
and implies that most of the variables are not highly correlated with each other. Condition
(C2) is also mild. For example, if max1≤i≤j≤p |ηi,j,d| = 1, then Ωd is singular. The following
theorem states the asymptotic null distribution for Mn.
Theorem 1—Suppose that (C1), (C2), (4) and (5) hold. Then under H0, for any t ε ℝ,
(15)

where Mn is defined in equation (10). Under H0, the convergence in (15) is uniform for all
{Xk : k = 1,…, n1} and {Yk : k = 1,…, n2} satisfying (C1), (C2), (4) and (5).

Author Manuscript

Equations (4) and (5) are mild conditions on the estimator of βi,d in order to obtain the
limiting distribution in Theorem 1. As discussed in Section 2 3, these conditions can be
guaranteed by the lasso estimator for example.
Corollary 1—Suppose that (C1) and (C2) hold and max1≤i≤p |βi,d|0 = o{n1/2 / (log p)3/2}.
Then under H0, for any κd > 2 in (13) and (14), and for any t ε ℝ,
(16)

where Mn is defined in (10).
3 2. Power Analysis

Author Manuscript

We now turn to an analysis of the power of the test ψα given in (11). We shall define the
following class of precision matrices:

(17)
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The next theorem shows that the null parameter set in which Ω1 = Ω2 is asymptotically
distinguishable from (4) by the test ψα. That is, H0 is rejected by the test ψα with
overwhelming probability if

.

Theorem 2—Let the test ψα be given as in (11). Suppose that (C1), (4) and (5) hold. Then

The following result shows that this lower bound is rate-optimal. Let
level tests, i.e., pr(Tα = 1) ≤ α under H0 for all
.

be the set of all α-

Author Manuscript

Theorem 3—Suppose that log p = o(n). Let α, β > 0 and α + β < 1. Then there exists a
constant c0 > 0 such that for all sufficiently large n and p,

Theorem 3 shows that, if c0 is sufficiently small, then any α level test is unable to reject the
null hypothesis correctly uniformly over
with probability tending to one.
So the order (logp)1/2 in the lower bound of max1≤i≤j≤p{|ωi,j,1 − ωi,j,2/(θi,j,1 + θi,j,2)1/2} in
(17) cannot be improved.

4. Multiple Testing with False Discovery Rate Control
Author Manuscript

If the global null hypothesis is rejected, it is often of interest to investigate the structure of
the differential network Δ. A natural approach is to carry out simultaneous testing on the
elements of Δ. In this section, we introduce a multiple testing procedure with false discovery
rate control for testing (p2 − p) /2 hypotheses
(18)

The standardized differences of Ti,j,1 and Ti,j,2 are defined by the test statistics
as in (9). Let t be the threshold level such that H0,i,j
is rejected if |Wi,j |≥ t. Let ℋ0 = {(i, j) : δi,j = 0,1 ≤ i < j ≤ p} be the set of true nulls. Denote

Author Manuscript

by
the total number of false positives, and by R(t) = Σ1≤i<j≤p
I(|Wi,j|≥ t) the total number of rejections. The false discovery proportion and false discovery
rate are defined as
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An ideal choice of t would reject as many true positives as possible while controlling the
false discovery rate and false discovery proportion at the pre-specified level α. That is, we
select

Since ℋ0 is unknown, we can estimate
by
as in
Liu (2013), where ϕ(t) is the standard normal cumulative distribution function. Note that
can be estimated by (p2 − p)/2 due to the sparsity of Δ. This leads to the following
multiple testing procedure.

Author Manuscript

1.

Calculate the test statistics Wi,j.

2.

For given 0 ≥ α ≥ 1, calculate

If does not exists, set
3.

.

For 1 ≤ i < j ≤ p, reject H0,i,i,. if and only if

.

The following theorem shows that, under regularity conditions, the above procedure controls
the false discovery proportion and false discovery rate at the pre-specified level α
asymptotically.

Author Manuscript

Theorem 4
Let

Suppose for some ρ > 0 and some δ > 0,
that

for any ν > 0, where

. Suppose
is given in Condition (C1). Assume that

for some c > 0, and (4) and (5) hold. Let q = (p2 − p)/2. Then under (C1)
with p ≤ cnr for some c > 0 and r > 0, we have

Author Manuscript

in probability, as (n, p) → ∞.
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The condition
in Theorem 4 is mild, since there are
2
(p − p)/2 hypotheses in total and this condition only requires a few entries with the
standardized difference having magnitude exceeding {(log p)1/2+ρ/n}1/2 for some constant ρ

> 0. The technical condition
for any ν > 0 is to ensure that most of the
regression residuals are not highly correlated with each other under the null hypotheses
H0,i,j : δi,j = 0.
The basic idea for the proof of Theorem 4 is similar to that in Liu (2013). However, the
setting here is more complicated as ωi,j,1 and ωi,j,2 are not necessarily zero under H0,i,j : δi,j
= 0. So the coordinates of the regression residuals in (2) and (3) can be correlated with each
other. Thus slightly stronger conditions are needed and the proof is more involved.

Author Manuscript

5. Simulation Study
The proposed testing procedures are easy to implement, and the Matlab code is available in
the Supplementary Material. We carry out a simulation study to investigate the numerical
performance, including the size and power, of the global test Ψα and the false discovery rate
controlled multiple testing procedure.
We first introduce the matrix models used in the simulations. Let D = (Di,j) be a diagonal
matrix with Di,i = Unif(0.5, 2.5) for i = 1,…,p. The following four models under the null,
, are used to study the size of the tests.
Model 1:

where

,

,

and

otherwise. Ω(1) = D1/2Ω*(1)D1/2.

Author Manuscript

Model 2:

for i = 10(k − 1) + 1 and 10(k − 1)

where

otherwise. Ω(2) = D1/2(Ω

+ 2 ≤ j ≤ 10(k − 1) + 10, 1 ≤ k ≤ p/10.
+ δ)D1/2 with δ = |λmin(Ω*(2))| + 0.05.
Model 3:

where

*(2)

+ δI)/(1

for i < j and

,

. Ω(3) = D1/2(Ω*(3)+ δI)/(1 + δ)D1/2 with δ = |λmin(Ω*(3))| + 0.05.
Model 4:

where

Author Manuscript

where k = 1,…, [p/2] and
with δ = |λmin(Σ*(4))| + 0.05.

,

for 2(k − 1) + 1 ≤ i ≠ j ≤ 2k,

otherwise. Ω(4) = d1/2{(Σ*(4) + δI)/(1 + δ)}−1 D1/2

For global testing of H0 : Δ = 0, the sample sizes are taken to be n1 = n2 = 100, while the
dimension p varies over the values 50, 100, 200 and 400. For each model, data are generated
from multivariate normal distributions with mean zero and covariance matrices
and

The nominal significance level for all the tests is set at α1 − 0.05.

To evaluate the power of the proposed tests, let U = (ui,j) be a matrix with eight random
nonzero entries. The locations of four nonzero entries are selected randomly from the upper
Biometrika. Author manuscript; available in PMC 2017 May 11.
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triangle of U, each with a magnitude generated randomly and uniformly from the set
[−2ω(log p/n)1/2, −ω(log p/n)1/2] ∪ [ω(log p/n)1/2,2 ω(log p/n)1/2], where
. The other four nonzero entries in the lower triangle are determined by
symmetry. We use the following four pairs of precision matrices

,

to show the power of the test, where
and
, with δ = |
(
m
)
(
m
)
min{λmin(Ω + U), λmin(Ω )}| + 0.05. The actual sizes and powers in percentage for the
four models, reported in Table 1, are estimated from 1000 replications.

Author Manuscript

are close to the nominal level in all cases.
Table 1 shows that the sizes of the global test
This reflects the fact that the null distribution of the test statistic Mn is well approximated by
its asymptotic distribution. The empirical sizes are slightly below the nominal level in some
models, due to the correlation among the variables. Similar phenomena have also been
observed in Cai et al. (2013) and are theoretically justified by their Proposition 1. Table 1
shows that the proposed test is powerful in all settings, although the two precision matrices
differ only in eight entries with the magnitude of the difference of the order (log p/n)1/2.
In addition, we consider nearer alternatives by generating the nonzero entries randomly and
uniformly from the set [−ω(2 log p/n)1/2, ω(2 log p/n)1/2]. The power results are summarized
in Table 2. Under the nearer alternatives, the magnitude of the standardized difference of Ω1
− Ω2 is smaller and as a result the power is lower.
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More extensive simulation results are presented in the Supplementary Material. The
proposed test significantly outperforms both that of Cai et al. (2013), which is powerful
when Σ1 − Σ2 is sparse under the alternative, and that of Li & Chen (2012), which is
powerful when Σ1 − Σ2 is dense under the alternative.
For simultaneous testing of the individual entries of the differential network Δ with false
discovery rate control, we select
making
as follows.

in (13) and (14) adaptively with the principle of
and

as close as possible. The algorithm is

1.
For any given i ∈{1,…,p}, let

and
for s = 1,…, 40. For each s, calculate

and d = 1,2. Based on the estimated regression coefficients,

Author Manuscript

construct the corresponding standardized difference
2.

Choose
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The tuning parameters are chosen to be

and

.
Pairwise comparisons among these four models are considered. The sample sizes are n1 = n2
= 100, while the dimension p = 50, 100, and 200. The false discovery rate level is set at α2 =
0.1, and the empirical false discovery rate and the power of false discovery rate control in
percentage, summarized in Table 3, are estimated from 100 replications. We examine the
power based on the average powers for 100 replications as follows

Author Manuscript

where Wi,j,l denotes standardized difference for the lth replication and
denotes the
nonzero locations. For all six cases, the false discovery rates are close to α across all
dimensions. For empirical power, the procedure is powerful when the dimension p is low,
and retains high power for the comparisons between Model 1 and Models 2 and 4. However,
for the comparison between Model 2 and Model 3, the power is low when dimension is high
and this is because all of | ωi,j,1 − ωi,j,2|/(θi,j,1n1 + θi,j,2n2)1/2 is smaller than 0.25 when p =
200 and D = I. Similarly, most nonzero entries of the standardized difference for Model 2
and 4 are smaller than 0.24. Thus it is difficult to detect nonzero locations. Furthermore,
under the same scenario, ωi,j/(θi,jn)1/2 is always smaller than 0.16 for Model 3, and thus the
detection becomes harder when we compare Model 3 with other models. Thus, the power
results are not good when Model 3 is included in the comparison.
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6. Real Data Analysis
The high throughput technology and massively parallel measurement of mRNA expression
catalyzed a new area of genomic biomarkers. A number of prominent genomic markers have
been identified to assist in predicting breast cancer patient survival in clinical practice, and
increasingly, pharmacogenomic endpoints are being incorporated into the design of clinical
trials (Olopade et al., 2008). Molecular pathways of pathogenesis for breast cancer have also
been increasingly discovered and curated (Nathanson et al., 2001). However, the role of
gene-by-gene interactions, within and across pathways, in breast cancer survival remain
unclear. Here, we apply our procedures to identify gene-by-gene interactions important for
breast cancer survival.

Author Manuscript

For illustration, we consider 32 pathways from the molecular signature database that are
related to breast cancer survival. Examples include the MAPK/ERK, WNT, TGF-β, P13kAKT-mTOR and ATRBRCA pathways. Existing literature has indicated that a defect in the
MAPK pathway may lead to uncontrolled growth, which is a step necessary for the
development of all cancers (Santen et al., 2002; Downward, 2003). Mutations or deregulated
expression of genes in the Wnt pathway can induce cancer (Klaus & Birchmeier, 2008). The
TGF-β signaling pathway is critical to a plethora of cellular processes including cell
proliferation, apoptosis and differentiation (Shi & Massagué, 2003). An increase in the TGFBiometrika. Author manuscript; available in PMC 2017 May 11.
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β2 expression is associated with response to tamoxifen for breast cancer patients (Buck &
Knabbe, 2006). The ATRBRCA pathway describes the role of BRCA1, BRCA2 and ATR in
cancer susceptibility (Venkitaraman, 2002). BRCA1 and BRCA2 are the best-known genes
linked to breast cancer risk. Hence, these pathways may play critical roles in breast cancer
progression. To examine the interactions between genes in these pathways, we applied our
procedure to a recent breast cancer gene expression study of 295 patients with primary
breast carcinomas from the Netherlands Cancer Institute (van de Vijver et al., 2002). Out of
the 32 pathways, there are a total of p = 754 genes with available data in this study. The two
populations we consider are the short term survivors, defined as those 78 patients who died
within 5 years; and the long term survivors, defined as those 69 patients who survived more
than 10 years. We are particularly interested in identifying gene pairs with interactive effects
on the binary cancer survival trait using the proposed procedures. In this setting, the sparsity
assumption about βi,k’s is reasonable as it is generally believed that transcriptional
regulation of a single gene is generally defined by a small set of regulatory elements (Segal
et al., 2003; Dobra et al., 2004).
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Based on our proposed procedures, we identified nine pairs of gene-by-gene interactions as
significant at a false discovery rate level of 0.1. An interaction here does not simply indicate
a co-expression between a pair of genes, but instead represents a difference between the coexpression patterns among the long terms survivors and among the short term survivors. As
shown in Figure 1, the majority of the genes involved in these interactions belong to five
major pathways, the MAPK, WNT, TGF-β, Apoptosis, and ATRBRCA pathways, although
many of these genes belong to multiple pathways. One pair of the identified interactions
represent gene-by-gene interactions within pathways and the remaining eight pairs represent
cross-talk between these pathways, some of which are previously documented. A total of
five interactions are between the MAPK signaling pathway and the WNT and TGF-β,
Apoptosis, ATRBRCA and MTA3 pathways. These cross-talks are not surprising since
MAPK modulates a wide range of processes including gene expression, mitosis,
proliferation, metabolism and apoptosis (Wada & Penninger, 2004). Several recent studies
suggest extensive crosstalk between WNT and MAPK signaling pathways in cancer. For
example, hyper-activation of MAPK signaling results in down-regulation of the WNT signal
transduction pathway in melanoma, suggesting a negative crosstalk between the two
pathways; while in colorectal cancer, stimulating the WNT pathway leads to activation of
the MAPK pathway through Ras stabilization, representing a positive crosstalk
(Guardavaccaro & Clevers, 2012). The observed interactive effect between the WNT and
MAPK pathways suggests that the cross-talk between these two pathways may play an
important role in breast cancer survival. The interaction between the tumor suppressor gene
BRCA2 and the MAPK pathway has been documented in experiments with prostate cancer
cells with upregulation of BRCA2 linked to an increase in MAPK activity (Moro et al.,
2007). In the WNT pathway, the WNT1 gene promotes cell survival in various cell types and
it has been experimentally shown that blocking WNT1 signaling can induce apoptotic cell
death (You et al., 2004). Thus the interaction between WNT1 gene and the PRKACB gene in
the Apoptosis pathway may also be crucial for breast cancer.
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A. Appendix: Proofs
A·1. Technical Lemmas
We prove the main results in this section. We begin by collecting technical lemmas proved in
the supplementary material. The first lemma is the classical Bonferroni inequality.
Lemma A1 (Bonferroni inequality)
Let

. For any k < [p/2], we have
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where

.

For d = 1, 2, let

, and define
for 1 ≤ i < j ≤ p and

.

Lemma A2
Suppose that Conditions (C1), (4) and (5) hold. Then
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and

for 1 ≤ i < j ≤ p, where
is the empirical covariance between {εk,i,d : k = 1, …, nd} and
{εk,j,d : k = 1, …, nd}. Consequently, uniformly in 1 ≤ i < j ≤ p,

and uniformly in 1 ≤ i ≤ p,
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where

is defined in (7),
and
.
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Let Xk ~ N(μ1, Σ1) for k = 1, …, n1 and Yk ~ N(μ2, Σ2) for k = 1, …, n2. Define
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uniformly for 0 ≤ x ≤ (8 log p)1/2 and any subset

Then, for some constant C > 0,

satisfies the large deviation bound

.

The following lemma is needed for false discovery rate control in Theorem 4.
Lemma A4
Let Vi,j = (Ui,j,2−Ui,j,1){var(εk,i,1εk,j,1)/n1 + var(εk,i,2εk,j,2)/n2}−1/2. Under the same
conditions as in Theorem 4, we have for any ε > 0 that,
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where tp = (4 log p − log2 p – log3 p)1/2 and vp = 1/{log p(log4 p)2}1/2.

A·2. Proof of Theorem 1
Without loss of generality, throughout this section, we assume that ωi,i,d = 1 for d = 1, 2 and
i = 1,…, p. Let A = {(i, j) : 1 ≤ i ≤ j ≤ p}. (C1) implies |Aτ|=o(p1/16). To prove Theorem 1,
we first show that the terms in Aτ are negligible. Then we use Lemma 1, together with the
Gaussian approximation technique, to show that
, where Wi,j is
defined in equation (9).
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For d = 1, 2, let Vi,j = (Ui,j,2 − Ui,j,1)/{var(εk,i,1εk,j,1)/n1 + var(εk,i,d εk,j,d)/n2}1/2, where
with

. The proof of Lemma 2

yields

(A1)
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and

, where n = max{n1, n2}. Note that

(A2)

and
Also note that for (i, j)
−1
∈ A\Aτ, we have |ωi,j,d| = o{(log p) }. Then by Lemma 2, it is easy to see that, under
conditions (C1), (4) and (5), we have, for (i, j) ∈ A\Aτ,
. For (i,j) ∈ Aτ as a result of Lemma 2, we
have Wi,j = Vi,j + bi,j + op 1og

p–1/2),

where
,
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,

and

.

Note that

where

. Thus, we have
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where the last equality is a direct result of Lemma 3. Thus it suffices to prove that

We arrange the indices {(i, j) : (i, j) ∈ A\Aτ} in any ordering and set them as {(im, jm) : m =
1, …, q} with q =Card(A\Aτ). Let n1/n2 ≤ K with K ≥ 1,

, for d = 1, 2
for 1 ≤ k ≤ n2,

and define

for n2 + 1 ≤ k ≤ n1 + n2,
and
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, where
, and τn = 32K1 log(p + n). Note that
, and that
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. By the fact that
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, it suffices to prove that for any t ∈ ℝ, as n, p → ∞,

(A3)

By Lemma 1, for any integer l with 0 < l < q/2,

(A4)
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where yp = 4 log p − log log p + t and

. Let

for m = 1, …, q and

n1 + n2. Define

for any vector a ∈

Rd.

, for 1 ≤ k ≤
Then we have

Then it follows from Theorem 1 in Zaïtsev (1987) that
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(A5)
where c1 > 0 and c2 > 0 are constants, εn → 0 which will be specified later and
is a normal random vector with E(Nd) = 0 and
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. Recall that d is a fixed integer which does not
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depend on n, p. Because
large M > 0

, we can let εn → 0 sufficiently slowly that, for any

(A6)

Combining (A4), (A5) and (A6) we have
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(A7)

Similarly, using Theorem 1 in Zaïtsev (1987) again, we can get

(A8)
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We recall the following lemma, which is shown in the supplementary material of Cai et al.
(2013).
Lemma A5
For any fixed integer d ≥ 1 and real number t ∈ ℝ,

(A9)
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It then follows from Lemma 5, (A7) and (A8) that
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for any positive integer l. By letting l → ∞, we obtain (A3) and Theorem 1 is proved.

A·3. Proof of Theorem 2
Let

. It follows from the
, as n, p → ∞. By (A1), (A2)

proof of Theorem 1 that
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and the inequalities

, and
, we have pr(Mn ≥ qα + 4 log p −

log log p) → 1 as n, p → ∞.

A·4. Proof of Theorem 3
To prove the lower bound result, we first construct the worst case scenario to test between Ω1
and Ω2, and then apply the arguments as shown in Baraud (2002).
Let ℳ denote the set of all subsets of {1,…, p} with cardinality pr, for r < 1/2. Let be a
random subset of {1,…, p}, which is uniformly distributed on ℳ. We construct a class of Ω1,
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, such that ωi,j = 0 for i ≠ j and
, for i, j = 1,…, p and ρ
= c(log p/n)1/2, where c > 0 will be specified later. Let Ω2 = I and Ω1 be uniformly
distributed on . Let μρ be the distribution of Ω1 − I. Note that μρ is a probability measure
on
, where
is the class of matrices with pr nonzero entries.
Let dpr1({Xn, Yn}) and dpr2({Xn, Yn}) be the functions with precision matrices Ω1 and Ω2
respectively, likelihood then we have

is the expectation on Ω1. By the arguments in Baraud (2002), it suffices to

where
show that
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where

. It is easy to check that

and

. Thus, we have
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Set Ωm + Ωm′ − 2I = (ai,j). It is easy to show that ai,j = 0 for i ≠ j, aj,j = 0 if j ε (m ∪ m′)c, aj,j
= 2(1/(1 + ρ)−1) if j ε m ∩ m′ and aj,j = 1/(1 + ρ) −1 if j ε m \ m′ \ m. Let t = | m ∩ m′|.
Then

Author Manuscript

for r < 1/2. Thus, by letting c be sufficiently small, we have

A·5. Proof of Theorem 4
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We first show that , as defined in Section 4, is obtained in the range (0, 2(log p)1/2). Then
we illustrate that R0(t), defined in Section 4, is close to 2 {1 − Φ(t)}|ℋ0| by first showing the
terms in Aτ are negligible. We then focus on the set ℋ0 \ Aτ and prove the result based on
Lemma 4.
Under the condition of Theorem 4, we have Σ1≤i<j≤p I{|Wi,j| ≥ 2(log p)1/2} ≥ [1/{(8π)1/2 α}
+ δ](log2 p)1/2, with probability going to one. Hence we have with probability going to one,

Let tp = (4 log p − log2 p − log3 p)1/2. Because
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have

, we

according to the definition of in the false discovery rate control

algorithm in Section 4. Note that, for

, we have
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Thus to prove Theorem 4, it suffices to prove that
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o(log

p)}1/2,

1.

in probability, for 0 ≤ t ≤ {4 log p +
where G(t) = 2{1 − Φ(t)}. Now we consider two cases.

If t = {4 log p + o(log p)}1/2, the proof of Theorem 1 yields that
. Thus, it suffices to prove that
probability. For (i, j) ∊ ℋ0 \
Aτ, we have from the proof of Theorem 1 that max1≤i<j≤p | Wi,j − Vi,j | = op {(log
p)−1/2}. Thus, it suffices to show that

(A10)
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in probability, where εi,j(t) = I(|Vi,j |≥ t) − G(t).
2.

If t ≤ (C log p)1/2 with C < 4, we have

in probability. Thus, it is again enough to show that
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(A11)

in probability. Define
. Let 0 ≤ t0 < ⋯ < tm = tp such that tl − tl−1 =
vp for l = 1,…, m − 1 and tm − tm−1 ≤ vp. Thus we have m·~ tp/vp. For any t such
that tl−1 ≤ t ≤ tl, we have
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Thus it suffices to prove
probability. Note that

Thus by (A5) with d = 1 and Lemma 4, Theorem 4 is proved.

Biometrika. Author manuscript; available in PMC 2017 May 11.

in

Xia et al.

Page 24

Author Manuscript

References

Author Manuscript
Author Manuscript
Author Manuscript

Anderson, TW. An Introduction To Multivariate Statistical Analysis. 3rd. New York: WileyIntersceince; 2003.
Baraud Y. Non-asymptotic minimax rates of testing in signal detection. Bernoulli. 2002; 8:577–606.
Breiman L. Random forests. Mach Learn. 2001; 45:5–32.
Buck MB, Knabbe C. TGF-Beta signaling in breast cancer. Ann N Y Acad Sci. 2006; 1089:119–126.
[PubMed: 17261761]
Cai T, Liu W, Xia Y. Two-sample covariance matrix testing and support recovery in high-dimensional
and sparse settings. J Am Statist Assoc. 2013; 108:265–277.
Chapman J, Clayton D. Detecting association using epistatic information. Genet Epidemiol. 2007;
31:894–909. [PubMed: 17654599]
Chatterjee N, Kalaylioglu Z, Moslehi R, Peters U, Wacholder S. Powerful multilocus tests of genetic
association in the presence of gene-gene and gene-environment interactions. Am J Hum Genet.
2006; 79:1002–1016. [PubMed: 17186459]
Danaher P, Wang P, Witten DM. The joint graphical lasso for inverse covariance estimation across
multiple classes. J R Statist Soc B. 2014; 76:373–397.
Dobra A, Hans C, Jones B, Nevins JR, Yao G, West M. Sparse graphical models for exploring gene
expression data. J Multivariate Anal. 2004; 90:196–212.
Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003; 3:11–22.
[PubMed: 12509763]
Eichler EE, Flint J, Gibson G, Kong A, Leal SM, Moore JH, Nadeau JH. Missing heritability and
strategies for finding the underlying causes of complex disease. Nat Rev Genet. 2010; 11:446–450.
[PubMed: 20479774]
Fan J, Lv J. Sure independence screening for ultra-high dimensional feature space (with discussion). J
R Statist Soc B. 2008; 70:849–911.
Gregg JP, Lit L, Baron CA, Hertz-Picciotto I, Walker W, Davis RA, Croen LA, Ozonoff S, Hansen R,
Pessah IN, et al. Gene expression changes in children with autism. Genomics. 2008; 91:22–29.
[PubMed: 18006270]
Guardavaccaro D, Clevers H. Wnt/β-Catenin and MAPK Signaling: Allies and enemies in different
battlefields. Sci Signal. 2012; 5 pe15.
Hu VW, Sarachana T, Kim KS, Nguyen A, Kulkarni S, Steinberg ME, Luu T, Lai Y, Lee NH. Gene
expression profiling differentiates autism case–controls and phenotypic variants of autism
spectrum disorders: evidence for circadian rhythm dysfunction in severe autism. Autism Res.
2009; 2:78–97. [PubMed: 19418574]
Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer.
2008; 8:387–398. [PubMed: 18432252]
Kooperberg C, Leblanc M. Increasing the power of identifying gene × gene interactions in
genomewide association studies. Genet Epidemiol. 2008; 32:255–263. [PubMed: 18200600]
Kooperberg C, Ruczinski I. Identifying interacting SNPs using Monte Carlo logic regression. Genet
Epidemiol. 2005; 28:157–170. [PubMed: 15532037]
Li J, Chen SX. Two sample tests for high-dimensional covariance matrices. Ann Statist. 2012; 40:908–
940.
Li KC, Palotie A, Yuan S, Bronnikov D, Chen D, Wei X, Choi OW, Saarela J, Peltonen L. Finding
disease candidate genes by liquid association. Genome Biol. 2007; 8:R205. [PubMed: 17915034]
Liu W. Gaussian graphical model estimation with false discovery rate control. Ann Statist. 2013;
41:2948–2978.
Marchini J, Donnelly P, Cardon L. Genome-wide strategies for detecting multiple loci that influence
complex diseases. Nat Genet. 2005; 37:413–417. [PubMed: 15793588]
Mechanic L, Luke B, Goodman J, Chanock S, Harris C. Polymorphism Interaction Analysis (PIA): a
method for investigating complex gene-gene interactions. BMC Bioinformatics. 2008; 9:146.
[PubMed: 18325117]

Biometrika. Author manuscript; available in PMC 2017 May 11.

Xia et al.

Page 25

Author Manuscript
Author Manuscript
Author Manuscript

Moore J. Computational analysis of gene-gene interactions using multifactor dimensionality reduction.
Expert Rev Mol Diagn. 2004; 4:795–803. [PubMed: 15525222]
Moro L, Arbini AA, Marra E, Greco M. Constitutive activation of MAPK/ERK inhibits prostate cancer
cell proliferation through upregulation of BRCA2. Int J Oncol. 2007; 30:217–224. [PubMed:
17143532]
Nathanson K, Wooster R, Weber B. Breast cancer genetics: what we know and what we need. Nat
Med. 2001; 7:552–556. [PubMed: 11329055]
Olopade O, Grushko T, Nanda R, Huo D. Advances in Breast Cancer: Pathways to Personalized
Medicine. Clin Cancer Res. 2008; 14:7988. [PubMed: 19088015]
Phillips PC. Epistasisthe essential role of gene interactions in the structure and evolution of genetic
systems. Nat Rev Genet. 2008; 9:855–867. [PubMed: 18852697]
Ritchie M, Hahn L, Roodi N, Bailey L, Dupont W, Parl F, Moore J. Multifactor-dimensionality
reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast
cancer. Am J Hum Genet. 2001; 69:138–147. [PubMed: 11404819]
Santen RJ, Song RX, Mcpherson R, Kumar R, Adam L, Jeng MH, Yue W. The role of mitogenactivated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol. 2002; 80:239–256.
[PubMed: 11897507]
Schott JR. A test for the equality of covariance matrices when the dimension is large relative to the
sample sizes. Comput Stat Data An. 2007; 51:6535–6542.
Segal E, Shapira M, Regev A, Pe’er D, Botstein D, Koller D, Friedman N. Module networks:
identifying regulatory modules and their condition-specific regulators from gene expression data.
Nat Genet. 2003; 34:166–176. [PubMed: 12740579]
Shi Y, Massagué J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell. 2003;
113:685–700. [PubMed: 12809600]
Srivastava MS, Yanagihara H. Testing the equality of several covariance matrices with fewer
observations than the dimension. J Multivariate Anal. 2010; 101:1319–1329.
van de Vijver M, He Y, Van’t Veer L, et al. A gene-expression signature as a predictor of survival in
breast cancer. N Engl J Med. 2002; 347:1999–2009. [PubMed: 12490681]
van’t Veer LJ, Dai H, Van De Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, Van Der Kooy K,
Marton MJ, Witteveen AT, et al. Gene expression profiling predicts clinical outcome of breast
cancer. Nature. 2002; 415:530–536. [PubMed: 11823860]
Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;
108:171–182. [PubMed: 11832208]
Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene. 2004;
23:2838–2849. [PubMed: 15077147]
You L, He B, Uematsu K, Xu Z, Mazieres J, Lee A, Mccormick F, Jablons DM. Inhibition of wnt-1
signaling induces apoptosis in β-catenin-deficient mesothelioma cells. Cancer Res. 2004;
64:3474–3478. [PubMed: 15150100]
Zaïtsev AY. On the gaussian approximation of convolutions under multidimensional analogues of sn
bernstein’s inequality conditions. Probab Theory Rel. 1987; 74:535–566.
Zerba K, Ferrell R, Sing C. Complex adaptive systems and human health: the influence of common
genotypes of the apolipoprotein E (ApoE) gene polymorphism and age on the relational order
within a field of lipid metabolism traits. Hum Genet. 2000; 107:466–475. [PubMed: 11140944]

Author Manuscript
Biometrika. Author manuscript; available in PMC 2017 May 11.

Xia et al.

Page 26

Author Manuscript
Author Manuscript

Fig. 1.

Identified gene-by-gene interactions for the breast cancer example. The dashed lines
between gene-paris represent detected interactions. Genes inside each circle belong to the
same pathway whose name is also shown.
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Author Manuscript

Empirical sizes and powers (%) for global testing with α1 = 0.05, n1 = n2 = 100, and 1000 replications.
p

Model 1

Model 2

Model 3

Model 4

Size
50

3.8

3.9

5.4

4.4

100

3.6

4.4

4.1

3.8

200

3.4

3.6

3.7

3.9

400

3.5

3.7

3.6

3.5

Power

Author Manuscript

50

100

98.7

95.6

81.6

100

99.7

96.6

95.1

77.8

200

93.1

88.2

93.6

72.1

400

86.3

73.1

77.7

70.7
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Table 2
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Empirical power (%) for global testing under nearer alternatives.
p

Model 1

Model 2

Model 3

Model 4

Power under nearer alternative
50

90.3

71.6

58.9

20.6

100

89.4

70.3

60.8

22.8

200

81.9

55.2

54.2

21.7

400

73.5

54.7

57.7

17.5
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64.2

61.1

200

9.7

200

67.9

9.5

100

50

10.5

50

100

Models 1, 2

p

20.6

38.3

65.6

10.4

10.0

11.0

Models 1, 3

Models 1, 4

17.1

19.3

35.7

11.2

12.1

12.6

Power

46.1

51.4

55.0

11.7

11.8

12.2

Empirical False Discovery Rate

Models 2, 3

21.7

25.1

30.2

11.6

11.4

11.5

Models 2, 4

11.3

18.2

26.1

10.3

9.5

10.2

Models 3, 4

Empirical false discovery rate and power (%) with α2 = 0.1, n1 = n2 = 100, and 100 replications.
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